Chris Liang Selected Research

Chris Liang Research Topics

Disease

13	Neoplasms (Cancer) 03/2022 - 07/2006
3	Lung Neoplasms (Lung Cancer) 01/2022 - 07/2011
2	Macular Degeneration (Age-Related Maculopathy) 10/2023 - 01/2017
2	Fatigue 01/2022 - 01/2017
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2021 - 01/2018
2	Neuroblastoma 10/2015 - 07/2015
1	Choroidal Neovascularization 03/2022
1	Body Weight (Weight, Body) 03/2022
1	Exanthema (Rash) 01/2022
1	Hemorrhage 01/2022
1	Leukopenia 01/2022
1	Lymphopenia (Lymphocytopenia) 01/2022
1	Brain Neoplasms (Brain Tumor) 11/2021
1	Renal Cell Carcinoma (Grawitz Tumor) 10/2021
1	Bone Diseases (Bone Disease) 04/2018
1	Prostatic Neoplasms (Prostate Cancer) 04/2018
1	Infections 01/2018
1	Cytopenia 01/2018
1	Nausea 01/2017
1	Anorexia 01/2017
1	Diarrhea 01/2017
1	Muscle Cramp (Cramp) 01/2017
1	Carcinogenesis 10/2015
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 11/2014
1	Neoplasm Metastasis (Metastasis) 07/2006

Drug/Important Bio-Agent (IBA)

7	Tyrosine Kinase InhibitorsIBA 11/2021 - 07/2011
6	vorolanibIBA 10/2023 - 01/2019
5	Anaplastic Lymphoma KinaseIBA 11/2021 - 07/2011
3	ensartinibIBA 11/2021 - 10/2015
2	tyrosine receptor (receptor, tyrosine)IBA 03/2022 - 07/2006
2	Phosphotransferases (Kinase)IBA 03/2022 - 07/2006
2	Alanine Transaminase (SGPT)IBA 01/2022 - 01/2017
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 01/2019
2	CrizotinibIBA 11/2021 - 10/2015
2	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 10/2021 - 07/2006
2	MTOR InhibitorsIBA 10/2021 - 05/2012
2	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2019 - 07/2006
2	Docetaxel (Taxotere)FDA Link 01/2018 - 07/2006
2	Proteins (Proteins, Gene)FDA Link 07/2011 - 07/2006
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 03/2022
1	Sunitinib (Sutent)FDA Link 03/2022
1	pembrolizumabIBA 01/2022
1	cyclopropapyrroloindoleIBA 01/2022
1	NivolumabIBA 01/2022
1	Immune Checkpoint InhibitorsIBA 01/2022
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2022
1	Everolimus FDA Link 10/2021
1	Circulating Tumor DNAIBA 11/2019
1	TabletsIBA 01/2019
1	X480IBA 04/2018
1	ElectrolytesIBA 01/2018
1	Transaminases (Aminotransferases)IBA 01/2017
1	Proto-Oncogene Proteins c-metIBA 06/2014
1	CM-118IBA 06/2014
1	Mechanistic Target of Rapamycin Complex 1IBA 05/2012
1	X-387IBA 05/2012
1	Mechanistic Target of Rapamycin Complex 2IBA 05/2012
1	TOR Serine-Threonine KinasesIBA 05/2012
1	5- ((5- fluoro- 2- oxo- 1,2- dihydro- 3H- indol- 3- ylidene)methyl)- N- (2- hydroxy- 3- morpholin- 4- ylpropyl)- 2,4- dimethyl- 1H- pyrrole- 3- carboxamideIBA 07/2006
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 07/2006
1	LigandsIBA 07/2006
1	Proto-Oncogene Proteins c-kit (Proto-Oncogene Protein c-kit)IBA 07/2006
1	fms-Like Tyrosine Kinase 3IBA 07/2006
1	Platelet-Derived Growth Factor beta Receptor (Receptor, Platelet Derived Growth Factor beta)IBA 07/2006

Therapy/Procedure

5	Therapeutics 07/2015 - 07/2006
1	Subcutaneous Injections 04/2018
1	Injections 01/2017
1	Oral Administration 06/2014